Page 48 - Genentech News Today

Among women with multiple sclerosis (MS), underrepresented women are less often employed and privately insured during pregnancy.

A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) -; soft tissue tumors that are stubbornly resistant to chemotherapy and radiation -; according to a laboratory study led by researchers at the Johns Hopkins Kimmel Cancer Center.

Biopharma Stock Breaking News - BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation

A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs), according to a laboratory study led by research

Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.

<p>Widespread availability of effective disease-modifying therapies would be a breakthrough in slowing the progression of early-stage Alzheimer’s disease. While there is substantial geographic variation across the U.S. to diagnose and treat early-stage Alzheimer’s disease with such therapies, engaging primary care providers in the effort may be a key to accelerating delivery of emerging new treatments, a study finds.</p>

A study on the effects of using omalizumab, in the treatment of food allergies, has shown an improved tolerance to a variety of everyday foods in children and adolescents.

The Boston-based drug maker plans to apply by the middle of the year to the FDA to approve the medicine, which, if approved, would represent the first new class of painkillers in decades.

There is substantial geographic variation across the U.S. health care system to diagnose and treat early-stage Alzheimer's disease with disease-modifying therapies, and engaging primary care providers in the effort may be a key to accelerating delivery of emerging new treatments, according to a new RAND report.

White mothers more often employed and privately insured; birthweight lower for babies born to underrepresented women.